How Long Can You Live With Bone Marrow Failure?

Survival with bone marrow failure ranges from months to decades, depending on the specific diagnosis, how severe the disease is, the patient’s age, and what treatment is available. A large cohort study found the overall median survival across both inherited and acquired forms was about seven years, rising to eight years in patients who received a bone marrow transplant.¹ But those numbers represent an average across very different situations. For younger patients with acquired aplastic anemia who respond well to modern therapy, long-term survival rates now exceed 80%, and many live essentially normal lifespans.²

Why There Is No Single Answer

“Bone marrow failure” is not one disease. It is an umbrella term for any condition where the marrow stops making enough blood cells. That can mean too few red cells, too few white cells, too few platelets, or all three at once. Some forms are acquired, meaning something goes wrong during your lifetime, usually an immune system attack on the marrow. Others are inherited, caused by genetic mutations present from birth. The most common acquired form is aplastic anemia. The inherited group includes conditions like Fanconi anemia, Diamond Blackfan anemia, and dyskeratosis congenita. Myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria overlap with bone marrow failure as well. Each of these diseases has its own trajectory, its own set of complications, and its own survival statistics.

This diversity is why the question “how long can you live” does not have a tidy answer. A 25-year-old with severe aplastic anemia who gets a matched-donor transplant faces a very different future than a 70-year-old with higher-risk myelodysplastic syndrome who cannot tolerate intensive therapy. The sections below break this down by condition and circumstance.

Acquired Aplastic Anemia

Aplastic anemia is the most common form of bone marrow failure that people develop during their lives. In severe cases, the immune system destroys the stem cells in the marrow, leading to dangerously low blood counts. Without treatment, severe aplastic anemia is usually fatal within months, primarily from infection or bleeding. With treatment, the picture is dramatically different.

The two main treatment paths are hematopoietic stem cell transplant (essentially a bone marrow transplant) and immunosuppressive therapy, which uses drugs to calm the immune attack so the marrow can recover. Swedish registry data showed a five-year survival rate of about 96% for patients who received a stem cell transplant, compared to roughly 69% for those treated with immunosuppressive therapy alone. Patients who received only minimal supportive care had a five-year survival of about 30%.³ In younger patients under 40, the gap between transplant and immunosuppressive therapy was much smaller, with both approaches yielding survival rates above 85%.

Long-term data are encouraging. A study following aplastic anemia patients for up to 30 years found overall survival of roughly 40 to 44% at that mark for both transplant and immunosuppressive therapy groups, with better results in patients treated in more recent eras.⁴ Among transplant patients who avoided chronic graft-versus-host disease, the 20-year survival probability was about 89%.⁵

Perhaps the most reassuring finding comes from conditional survival analysis. For patients with severe aplastic anemia who survived at least one year after treatment, mortality risk steadily declined and became comparable to the general population by five years out.⁶ In practical terms, if you make it through the first year and your counts recover, the odds of living a normal lifespan are good.

What Drives the Differences in Outcome

Several factors strongly influence how long a person with bone marrow failure can expect to live. The large cohort study mentioned earlier identified the most important ones. Age stands out: patients over 60 had more than three times the risk of death compared to those under 30. Patients between 31 and 60 had roughly double the risk.¹ This reflects both the body’s declining ability to recover and the increased likelihood of other health problems complicating treatment.

Other factors that predicted better survival included being female, receiving a bone marrow transplant, responding to first-line therapy, and, interestingly, evolving to paroxysmal nocturnal hemoglobinuria (a related condition that, while serious, tends to respond well to modern treatment). On the other hand, having all three blood cell lines affected at once, known as trilineage cytopenia, nearly tripled the risk of death compared to having just one or two cell lines affected.¹

Older adults face a particularly complicated situation. The treatment decision process for patients over 60 involves weighing not only the severity of the marrow failure itself but also overall fitness, other medical conditions, and available social support. These factors can rule out intensive therapies that would be standard for a younger patient.⁷ Without treatment, their prognosis is poor.

Telomere length, a molecular marker of cellular aging, has also emerged as a predictor. In patients with severe aplastic anemia treated with immunosuppressive therapy, shorter telomeres were associated with higher rates of relapse, transformation to more dangerous blood cancers, and death.⁸ This helps doctors identify which patients need more aggressive treatment early on.

How Modern Treatment Has Reshaped Survival

The story of bone marrow failure survival is largely a story of improving treatment. Aplastic anemia was once almost universally fatal. Standard immunosuppressive therapy, typically combining antithymocyte globulin and cyclosporine, changed that. But even standard immunosuppression has limitations: about a third of patients do not respond adequately, and relapse rates remain meaningful.

The addition of eltrombopag, a drug that stimulates platelet production and appears to help stem cells recover, has been a significant advance. A phase 2 trial combining eltrombopag with standard immunosuppressive therapy achieved an overall response rate of 94% in its most optimized dosing group, compared to a historical rate of about 66% with immunosuppression alone. The complete response rate jumped from 10% historically to 58%. At two years of follow-up, the survival rate was 97%.⁹ A systematic review and meta-analysis confirmed that adding eltrombopag improved overall survival compared to immunosuppression alone.¹⁰

For transplant, outcomes have improved with better donor matching, refined conditioning regimens, and improved management of graft-versus-host disease. When no matched sibling or unrelated donor is available, haploidentical transplants, using a half-matched family member, now represent a viable alternative, particularly for children with inherited bone marrow failure syndromes.¹¹

Inherited Bone Marrow Failure Syndromes

Inherited forms of bone marrow failure are rarer and typically diagnosed in childhood. They carry unique challenges because the underlying genetic defect affects the body beyond just the marrow, including a heightened risk of cancer that persists even after a successful transplant.

Fanconi Anemia

Fanconi anemia is the most well-known inherited bone marrow failure syndrome. Data from the Italian registry found a cumulative overall survival from birth of about 91% at age 10, dropping to roughly 72% at age 20 and 47% at age 30. The median survival age was about 29 years.¹² The biggest threats beyond marrow failure itself are infections and cancers, particularly squamous cell carcinomas of the head and neck. Cancer incidence rose sharply after age 20, reaching about 52% by age 40.

Transplant can cure the marrow failure component of Fanconi anemia, with 10- and 15-year post-transplant survival probabilities of about 90% and 79%, respectively. But transplant does not eliminate the cancer risk. In fact, the cancer risk was higher in transplanted patients, likely due to the conditioning treatments and chronic graft-versus-host disease.¹³ Squamous cell carcinoma was the predominant cause of late deaths after transplant, with incidence rising over time.

Diamond Blackfan Anemia

Diamond Blackfan anemia primarily affects red blood cell production. Patients often respond to corticosteroids or regular transfusions, and some enter spontaneous remission. The outlook is notably better than Fanconi anemia: registry data found a median survival of 56 years, with the cumulative incidence of solid tumors or leukemia reaching about 20% by age 46.¹⁴ While Diamond Blackfan anemia is still a cancer predisposition syndrome, the risks appear lower than in Fanconi anemia or dyskeratosis congenita.

Myelodysplastic Syndromes

Myelodysplastic syndromes sit at the intersection of bone marrow failure and blood cancer. The marrow produces blood cells, but they are defective, leading to low counts and a risk of progression to acute myeloid leukemia. Because MDS encompasses a wide spectrum of subtypes, survival varies enormously. The Revised International Prognostic Scoring System divides patients into risk groups ranging from very low to very high. Median survival spans from a few months for the highest-risk patients to many years for those in lower-risk categories.¹⁵

For lower-risk MDS, progression to higher-risk disease or acute leukemia is the main concern over time. A study tracking lower-risk patients found that those who stayed in the lower-risk category had a median overall survival of about 81 months, while those who progressed to high-risk MDS or leukemia had median survivals ranging from roughly 43 to 61 months, depending on the pattern of progression.¹⁶ For higher-risk MDS, the picture is grimmer. One prospective study of patients with higher-risk disease found a median overall survival from diagnosis of just 17 months.¹⁷

Because MDS disproportionately affects older adults, many patients face the added complication of other age-related health problems that limit treatment options. Transplant can be curative for eligible patients, but many are too old or too frail for it.

Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal nocturnal hemoglobinuria, or PNH, is a condition that frequently overlaps with aplastic anemia. In PNH, a genetic change in blood stem cells makes red blood cells vulnerable to destruction by the complement system, a part of the immune response. Before modern treatment, PNH shortened life significantly, with life-threatening blood clots as a major killer.

The development of complement inhibitors, starting with eculizumab, transformed the outlook. These drugs block the immune pathway that destroys red blood cells, and studies describe the result as near-normal life expectancy for patients on treatment.¹⁸ ¹⁹ In the large bone marrow failure cohort study, evolution to PNH was actually associated with better survival, likely because PNH itself responds so well to current therapy.¹

The Complications That Shorten Lives

Across all forms of bone marrow failure, the immediate threats to life come from the consequences of low blood counts rather than the marrow failure itself. Understanding these helps explain why survival varies so much even within the same diagnosis.

Infection is the leading killer. When the marrow fails to produce enough white blood cells, particularly neutrophils, the body cannot fight off bacteria and fungi effectively. Invasive fungal infections have historically been the major cause of death in severe aplastic anemia.²⁰ While antifungal drugs have improved, prolonged periods of very low neutrophil counts remain dangerous. In congenital forms of neutropenia, granulocyte colony-stimulating factor therapy has reduced the frequency and severity of infections, but the risk of eventually developing leukemia complicates long-term use.²¹

Bleeding is the other acute threat. Bone marrow failure often causes severely low platelet counts, making patients vulnerable to hemorrhage. Even with prophylactic platelet transfusions, life-threatening bleeding events still occur.²² The risk is highest during the periods of deepest cytopenia, either before treatment takes effect or during the recovery phase after transplant.

Over the longer term, iron overload becomes a slow-burning problem. Patients who depend on regular red blood cell transfusions accumulate iron that the body cannot excrete. This excess iron deposits in organs, particularly the heart and liver. In lower-risk MDS, transfusion-related iron overload has an independent negative effect on survival beyond the marrow failure itself. The iron can worsen heart function, damage blood vessels, and even further suppress the failing marrow.²³ Iron chelation therapy can mitigate this, but it requires ongoing treatment and monitoring.

Finally, the risk of the marrow failure evolving into a more aggressive blood cancer hangs over many patients. In the large cohort study, about 20% of inherited bone marrow failure patients developed myelodysplastic syndrome, and about 11% of acquired bone marrow failure patients did the same. Progression to acute myeloid leukemia occurred in a smaller percentage, but the time from diagnosis to that progression was shorter in inherited cases.¹

How Fatigue Relates to Survival

An underappreciated aspect of bone marrow failure is the impact of symptoms on both quality of life and, it turns out, actual survival. In higher-risk MDS, researchers found that patient-reported fatigue severity at diagnosis was independently associated with shorter survival, even after accounting for known risk factors like disease subtype and blood counts. For every ten-point worsening in fatigue scores, the risk of death increased by about 11%.¹⁷ This is not just about feeling tired. Severe fatigue in these patients likely reflects the depth of the underlying marrow failure and anemia in ways that standard lab tests do not fully capture. It also highlights that how a person feels can carry real prognostic weight, not only for doctors making treatment decisions but for patients trying to understand their own trajectory.

Gene Therapy on the Horizon

For inherited bone marrow failure syndromes, the major limitation of transplant is that it fixes the marrow but does not correct the underlying genetic defect in other tissues, and it comes with its own risks, including graft-versus-host disease and an increased cancer susceptibility. Gene therapy aims to sidestep these problems entirely by correcting the defective gene in a patient’s own stem cells, eliminating the need for a donor.

Work on gene therapy for Diamond Blackfan anemia has been particularly active. Researchers have used lentiviral vectors to deliver a corrected copy of the RPS19 gene, one of the most commonly mutated genes in Diamond Blackfan anemia, into patient stem cells. Preclinical experiments showed that this approach restored the ability of those cells to develop into red blood cells and demonstrated long-term engraftment potential.²⁴ Multiple research groups are now working toward bringing autologous gene therapy to clinical trials that would span the full age range of Diamond Blackfan anemia patients.²⁵ If successful, gene therapy could eventually shift the survival conversation for inherited marrow failure from managing a lifelong disease to something closer to a one-time correction, though clinical proof is still years away.

1
Blood. Deciphering the Differential Diagnosis of Inherited Versus Acquired Bone Marrow Failure Syndromes: A Large Cohort Study
2
PubMed Central. Aplastic Anemia
3
Haematologica. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011
4
PubMed Central. Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation
5
PubMed. Long-term outcome after marrow transplantation for severe aplastic anemia
6
PubMed Central. Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
7
Textbook of Bone Marrow Failure. Treatment of Elderly Patients with Aplastic Anemia
8
PubMed Central. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia
9
PubMed Central. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
10
PubMed Central. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis
11
PubMed. HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes
12
PubMed Central. Long‐Term Outcome of Fanconi Anemia Patients From the Italian Registry
13
PubMed. Long-term Survival, Organ Function, and Malignancy after Hematopoietic Stem Cell Transplantation for Fanconi Anemia
14
PubMed Central. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry
15
PubMed Central. Myelodysplastic syndromes: diagnosis, prognosis, and treatment
16
PubMed Central. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
17
The Lancet Oncology. Self-reported fatigue severity and survival in patients with higher-risk myelodysplastic syndromes
18
PubMed Central. A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria
19
PubMed. Paroxysmal nocturnal hemoglobinuria: Where are we going
20
PubMed. Approach to management of fever and infection in patients with primary bone marrow failure and hemoglobinopathies
21
Haematologica. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia
22
PubMed Central. Pathophysiology and management of thrombocytopenia in bone marrow failure
23
PubMed. Iron overload in myelodysplastic syndromes (MDS)
24
PubMed Central. Lentivirus-mediated gene therapy corrects ribosomal biogenesis and shows promise for Diamond Blackfan anemia
25
PubMed Central. Hematopoietic cell transplantation and gene therapy for Diamond-Blackfan anemia: state of the art and science